First published 10/3/2026, 11:23:15 PM · Last updated 10/3/2026, 11:23:15 PM

Clinical Impact of Trastuzumab Deruxtecan in Patients With HER2-Positive Advanced Gastric Cancer and Ascites: Findings From the EN-DEAVOR Study

Journal article reporting findings from the EN-DEAVOR study on the clinical impact of trastuzumab deruxtecan in patients with HER2-positive advanced gastric cancer and ascites.

Illustrative image: Abb. 44, page 140 Woman suffering from ascites; accumulation of excess fluid in the abdominal cavity. This is often associated with cirrhosis. General Collections Keywords: Liver Cirrhosis; Physiognomy; Ascites — https://wellcomeimages.org/indexplus/obf_images/4a/91/95cdee2ef0eef98d7801d28351bc.jpg Gallery: https://wellcomeimages.org/indexplus/image/L0074302.html Wellcome Collection gallery (2018-04-06): https://wellcomecollection.org/works/uhyyjmyu CC-BY-4.0/Wikimedia Commons, CC BY 4.0

Categories: public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 5/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 5/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The article presents clinical findings relevant to treatment of HER2-positive advanced gastric cancer patients with ascites.

Sources

Clinical Impact of Trastuzumab Deruxtecan in Patients With HER2-Positive Advanced Gastric Cancer and Ascites: Findings From the EN-DEAVOR StudyMetadata provided by Crossref. Usage terms

Report an issue